Half Year Results

Half Year Results

Manchester, UK - 21 February 2018 - SkinBioTherapeutics plc (AIM: SBTX or the "Company") a life sciences company focused on skin health, has announced its half year results for the six months to 31 December 2017....

21st February, 2018 Read More

Notice of Interim Results

Notice of Interim Results

Manchester, UK - 16 February 2018 - SkinBioTherapeutics plc (AIM: SBTX or the "Company") a life sciences company focused on skin health, will publish its interim results for the six months to 31 December 2017 on 21 February 2018....

16th February, 2018 Read More

Presentation at Shares Investor Evenings in Manchester and Edinburgh

Presentation at Shares Investor Evenings in Manchester and Edinburgh

Company CEO Cath O'Neill is to present at the Shares Investor Evenings in Manchester and Edinburgh where she'll be talking about SkinBioTherapeutics' history and strategy for 2018. The Shares and AJ Bell Media evening event is an opportunity for senior board directors from fast growing listed PL...

24th January, 2018 Read More

Appointment of Joint Broker

Appointment of Joint Broker

Manchester, UK - 5 January 2018 - SkinBioTherapeutics plc (AIM: SBTX, the "Company"), a life science company focused on skin health, announces the appointment of Northland Capital Partners to act as the Company's Joint Corporate Broker, alongside Turner Pope Investments, with immediate ef...

5th January, 2018 Read More

Notification of first patent grant

Notification of first patent grant

Manchester, UK - 1 December 2017 - SkinBioTherapeutics plc (AIM: SBTX, the "Company"), a life science company focused on skin health, announces the granting of the first patent for its SkinBiotix® technology in Australia....

4th December, 2017 Read More

SkinBiotix® platform passes additional external toxicity tests

SkinBiotix® platform passes additional external toxicity tests

Scientific progress on track Manchester, UK - 9 November 2017 - SkinBioTherapeutics plc (AIM: SBTX or the "Company"), a life science company focused on skin health, has passed two additional and final third party cellular toxicity tests for its SkinBiotix® technology....

9th November, 2017 Read More
investors logo